Future Outlook of the Liver Metastases Treatment Market: Growth, Trends, and Emerging Opportunities Explored
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the liver metastases treatment market?
There has been significant growth in the liver metastases treatment market size in the past few years. The market, which is set to expand from $1.57 billion in 2024 to $1.71 billion in 2025, is projected to have a compound annual growth rate (CAGR) of 8.9%. The historic period growth is a result of the broader adoption of personalized medicine, improved healthcare accessibility, advanced multidisciplinary care, as well as an increase in clinical trials and research initiatives.
What will be the liver metastases treatment market size in the future?
In the coming years, the liver metastases treatment market is anticipated to witness robust growth. It is projected to reach $2.37 billion in 2029, with a compound annual growth rate (CAGR) of 8.5%. The growth during the estimated period can be credited to factors such as patient-focused care models, precision medicine, a transition towards outpatient, ambulatory care, and regulatory initiatives. The forecast period will likely be marked by major trends like next-generation sequencing technologies, progress in immuno-oncology, the advent of liquid biopsy technologies, and adjuvant therapies.
Get your liver metastases treatment market report here!
https://www.thebusinessresearchcompany.com/report/liver-metastases-treatment-global-market-report
What main drivers are fueling expansion in the liver metastases treatment market?
The surge in liver disease cases is anticipated to drive the growth of the liver metastases treatment market. The term liver disease encompasses any ailment affecting the liver that could impede its normal functioning or proper operation. By safeguarding liver function, which is vital for metabolic processes, detoxification, and other key bodily functions, metastasis treatments enhance overall health. Furthermore, in certain scenarios, rigorous treatments like surgical resection, ablation, or targeted therapies are required for prolonged remission, particularly when combined with systemic drugs like chemotherapy or immunotherapy. For instance, Cancer Australia, a government cancer agency based in Australia, reported in September 2022 that approximately 2,905 new cases of liver cancer (2,113 males and 792 females) were diagnosed in Australia that year. Additionally, the likelihood of being diagnosed with liver cancer by the age of 85 is forecasted to be 1 in 103 (or 0.97%) in 2022, 1 in 70, or 1.4%, for men, and 1 in 195, or 0.51%, for women. As a result, the escalating incidences of liver disease are fuelling the growth of the liver metastases treatment market.
What key areas define the segmentation of the global liver metastases treatment market?
The liver metastases treatment market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Primary Cancer: Colorectal Cancer, Breast Cancer
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Subsegments:
1) By Chemotherapy: Cytotoxic Chemotherapy, Neoadjuvant Chemotherapy, Adjuvant Chemotherapy
2) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, MTOR Inhibitors
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer Therapy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15849&type=smp
Who are the dominant players expanding their reach in the liver metastases treatment market?
Major companies operating in the liver metastases treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, Bristol Myers Squibb, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Gilead Sciences Inc., Takeda Pharmaceutical Company, Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Eisai Co. Ltd., Incyte Corporation, Ipsen, Seattle Genetics, Exelixis Inc., Array BioPharma Inc., Genentech Inc., Clovis Oncology, Agios Pharmaceuticals Inc., Taiho Pharmaceutical Co.Ltd
What emerging trends are influencing the growth of the liver metastases treatment market?
Leading corporations in the liver metastases treatment market are prioritizing the development of liver-targeted therapies to provide effective and user-friendly treatments. Liver-targeted therapies are medicines or treatments that focus specifically on liver diseases or conditions. These therapies treat liver metastases by concentrating on cancerous cells in the liver, either obliterating them directly or interrupting their blood supply, using techniques such as surgical resection, radiofrequency ablation, transarterial chemoembolization, radioembolization, and stereotactic body radiation therapy. For example, in August 2023, the American interventional oncology company, Delcath Systems Incorporated, unveiled the Hepzato kit, a liver-targeted treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or limited extrahepatic disease amenable to resection or radiation. The Hepzato kit is a combined product that delivers melphalan, a chemotherapeutic agent, directly to the liver through Delcath’s Hepatic Delivery System (HDS), promoting higher drug exposure in target tissues while reducing systemic toxicity.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15849
Which regions are emerging as leaders in the liver metastases treatment market?
North America was the largest region in the liver metastases treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver metastases treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Chronic Myeloid Leukemia Treatment Global Market Report 2024
Crohn’s Disease (CD) Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report
Merkel Cell Carcinoma Treatment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
